Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly

J Clin Endocrinol Metab. 2002 Sep;87(9):4193-7. doi: 10.1210/jc.2002-020453.

Abstract

Experimental data support a role for GH and IGF-I in the reproductive process in humans, but the effect of chronic GH excess on gonadal and reproductive function in men has been never investigated. To understand the effects of short-term GH and IGF-I suppression on the gonadal axis and seminal fluid characteristics in men with acromegaly, we evaluated 35 patients (age 27-59 yr) with active disease and 35 age-matched healthy controls. Gonadal hormones and seminal fluid analysis were evaluated before and 6 months after surgery or lanreotide (LAN) (60 mg/month). At study entry, FSH, testosterone (T), and dihydrotestosterone (DHT) (P < 0.0001) levels, seminal volume, sperm count, total motility and forward progression, normal morphology, and vitality were significantly lower in patients with acromegaly than in controls. After 6 months, 22 patients achieved disease control after surgery (n = 11) or LAN (n = 11), whereas 13 had uncontrolled disease. Serum T and DHT levels and sperm number significantly increased in all groups. FSH and LH levels and total motility increased only in patients achieving disease control. Posttreatment IGF-I levels significantly correlated with total motility (r = -0.45; P = 0.006). In conclusion, short-term GH and IGF-I suppression after surgery or LAN significantly increased T and DHT levels and improved sperm number and motility in acromegalic men.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Acromegaly / drug therapy*
  • Acromegaly / etiology
  • Acromegaly / physiopathology
  • Adenoma / complications
  • Adult
  • Androgen Antagonists / therapeutic use*
  • Dihydrotestosterone / blood
  • Disease Progression
  • Estradiol / blood
  • Follicle Stimulating Hormone / blood
  • Human Growth Hormone / antagonists & inhibitors*
  • Human Growth Hormone / blood
  • Humans
  • Insulin-Like Growth Factor I / antagonists & inhibitors*
  • Insulin-Like Growth Factor I / metabolism
  • Luteinizing Hormone / blood
  • Male
  • Middle Aged
  • Peptides, Cyclic / therapeutic use*
  • Pituitary Neoplasms / complications
  • Regression Analysis
  • Somatostatin / analogs & derivatives
  • Somatostatin / therapeutic use*
  • Sperm Count*
  • Sperm Motility / drug effects
  • Testosterone / blood

Substances

  • Androgen Antagonists
  • Peptides, Cyclic
  • Dihydrotestosterone
  • lanreotide
  • Human Growth Hormone
  • Testosterone
  • Estradiol
  • Somatostatin
  • Insulin-Like Growth Factor I
  • Luteinizing Hormone
  • Follicle Stimulating Hormone